<DOC>
	<DOCNO>NCT00004123</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining radiation therapy chemotherapy may kill tumor cell . PURPOSE : Phase I trial study effectiveness radiation therapy plus doxorubicin treating patient resectable primary recurrent peritoneal soft tissue sarcoma .</brief_summary>
	<brief_title>Radiation Therapy Plus Doxorubicin Treating Patients With Resectable Primary Recurrent Retroperitoneal Soft Tissue Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity maximum tolerate dose preoperative external beam radiotherapy combine doxorubicin follow intraoperative radiotherapy patient resectable primary recurrent soft tissue sarcoma retroperitoneum . II . Assess radiologic pathologic response patient treat preoperative regimen . OUTLINE : This dose-escalation study external beam radiotherapy . Patients receive doxorubicin IV bolus follow immediately doxorubicin IV 4 day every week 5 week concurrently external beam radiotherapy 5 day week 4 week . Patients stable respond disease undergo surgical resection primary tumor adjacent gross disease approximately 6 week completion chemoradiotherapy . Patients receive intraoperative radiotherapy ( IORT ) tumor bed gross disease resect area maximal tumor adherence retroperitoneum encompass within single IORT field ( maximum 15 cm ) . Cohorts 3-6 patient receive escalate dos external beam radiotherapy maximum tolerate dose ( MTD ) determine . The MTD define dose 30 % patient experience grade 3 bad dose-limiting toxicity . PROJECTED ACCRUAL : A total 15-45 patient accrue study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven resectable primary recurrent soft tissue sarcoma retroperitoneum Greatest dimension 3dimensional assessment tumor size must 535 cm Grade 2 3 , include dedifferentiate liposarcoma retroperitoneal recurrence gastrointestinal leiomyosarcoma PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Zubrod 0 1 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 2,000/mm3 Platelet count least 100,000/mm3 Hepatic : Not specify Renal : Renal function normal Creatinine le 1.6 mg/dL Gastrointestinal : Must maintain adequate oral nutrition ( 90100 % estimate need calorie protein ) free nausea vomit prior radiotherapy ( feed tube allow ) Other : Prior malignancy allow discretion protocol investigator No serious uncontrolled medical condition Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : No prior abdominal radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>adult leiomyosarcoma</keyword>
	<keyword>adult liposarcoma</keyword>
	<keyword>stage III adult soft tissue sarcoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>stage II adult soft tissue sarcoma</keyword>
</DOC>